List of Neurontin drug patents
Neurontin is owned by Viatris.
Neurontin contains Gabapentin.
Neurontin has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Neurontin are:
- US7256216
- US7256216*PED
Neurontin was authorised for market use on 02 March, 2000.
Neurontin is available in solution;oral dosage forms.
The generics of Neurontin are possible to be released after 28 November, 2022.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7256216 | VIATRIS | Liquid pharmaceutical compositions |
May, 2022
(1 year, 4 days ago) | |
|
US7256216 (Pediatric) | VIATRIS | Liquid pharmaceutical compositions |
Nov, 2022
(6 months ago) | |
Drugs and Companies using GABAPENTIN ingredient
Market Authorisation Date: 02 March, 2000
Treatment: NA
Dosage: SOLUTION;ORAL
NEURONTIN family patents
4
United States
1
Panama
1
IB
1
Spain
1
Hong Kong
1
Austria
1
Dominican Republic
1
Malaysia
1
Iceland
1
Denmark
1
AP
1
Czech Republic
1
Poland
1
Germany
1
China
1
Yugoslavia
1
Brazil
1
Canada
1
Estonia
1
Morocco
1
Ukraine
1
Argentina
1
EA
1
Norway
1
Japan
1
OA
1
New Zealand
1
Croatia
1
Korea, Republic of
1
Guatemala
1
Peru
1
Portugal
1
El Salvador
1
Georgia
1
Mexico
1
Australia
1
Costa Rica
1
Ecuador
1
Bulgaria
1
South Africa
1
Slovakia
1
Egypt
1
Tunisia
1
Slovenia
1
Hungary
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic